Ipsen

Ipsen, a pharmaceutical preparation manufacturer headquartered in France, has outlined robust climate commitments and emissions reporting. For the most recent reporting year, 2024, Ipsen reported total global GHG emissions of approximately 100.9 million kg CO2e. This includes Scope 1 emissions totalling around 9.93 million kg CO2e, and Scope 2 emissions, calculated on a market-based approach, of approximately 289,000 kg CO2e. A significant portion of their emissions, around 90.7 million kg CO2e, falls under Scope 3, with purchased goods and services being the largest contributor at approximately 60.5 million kg CO2e.

Ipsen has set ambitious science-based targets to align with the Paris Agreement's goal of limiting global warming to 1.5°C. The company is committed to reducing its absolute Scope 1 and 2 GHG emissions by 50% by 2030, using 2019 as a baseline year. Additionally, Ipsen aims for a 20% reduction in its Scope 3 emissions within the same timeframe. Looking further ahead, Ipsen's long-term target is to achieve science-based net-zero emissions by 2045. This involves reducing absolute Scope 1, 2, and 3 GHG emissions by at least 90% from the 2019 baseline and balancing any residual emissions with high-quality carbon removal. Ipsen is currently reporting progress towards these targets, indicating that its Scope 1 and 2 emissions reduction efforts are on track.